培元通脑胶囊联合他汀类药物治疗肾虚型动脉粥样硬化的疗效

Effect of Peiyuan Tongnao Capsule combined with statins on atherosclerosis of kidney deficiency

目的探讨培元通脑胶囊联合他汀类药物治疗肾虚型动脉粥样硬化(AS)患者的临床疗效。方法将120例肾虚型AS患者随机分为对照组和观察组,每组各60例,两组均口服辛伐他汀片,观察组同时口服培元通脑胶囊。比较两组患者的中医证候疗效、不良反应以及治疗前及治疗后6个月血管结构和中医症候评分。结果治疗后两组患者的中医证候评分、颈动脉内膜中层厚度(cI MT)和斑块面积均较治疗前明显下降,且观察组低于对照组(均P<0.05)。观察组疗效优于对照组,且总有效率高于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论在口服他汀类药物的基础上,培元通脑胶囊治疗肾虚型AS患者具有较好的临床疗效,可以明显缩小患者的cI MT和斑块面积,改善中医证候群,安全性较好。

Objective To investigate the clinical efficacy of Peiyuan Tongnao Capsule combined with statins on patients with atherosclerosis （AS） of kidney deficiency. Methods A total of 120 patients with AS of kidney deficiency were radomly divided into control group and observation group,with 60 cases in each group.Both groups were given simvastatin tablets orally,besides,the observation group was given Peiyuan Tongnao Capsule orally.The traditional Chinese medicine（TCM） symptom efficacy and adverse reactions,as well as vascular structure and TCM symptom score before treatment and at 6 months after treatment,were compared between the two groups. Results After treatment,the TCM syndrome score,carotid intima-media thickness（cIMT） and plaque area decreased significantly in both groups compared to those before treatment,and the indices above in the observation group were lower than those in the control group（all P 〈0.05） .The observation group had a better efficacy and a higher total effective rate compared to the control group（ P 〈0.05）.There was no statistically significant difference in the incidence rate of adverse reactions between the two groups（ P 〉0.05）. Conclusion On the basis of oral statins,Peiyuan Tongnao Capsule has better clinical efficacy on patients with AS of kidney deficiency,achieving significantly decreased cIMT and plaque area,improved TCM symptom and better safety.